Hanall Biopharma Market Cap ($1.29 Billion)
Market Cap & Net Worth: Hanall Biopharma (009420)
Hanall Biopharma market cap. Hanall Biopharma (KO:009420) has a market capitalization of $1.29 Billion (₩1.90 Trillion) as of November 1, 2026. Listed on the KO stock exchange, this Korea-based company holds position #7537 globally and #186 in its home market, demonstrating a -6.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hanall Biopharma's stock price ₩37500.00 by its total outstanding shares 50754857 (50.75 Million). Also see 009420 cash generation efficiency for how efficiently the company converts equity into cash flow.
Hanall Biopharma Market Cap History (2015–2026)
Hanall Biopharma market cap history from 2015 to 2026. Data shows growth from $452.31 Million to $1.29 Billion (10.75% CAGR). Check Hanall Biopharma stock price for real-time trading data and today's change.
Hanall Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hanall Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 009420 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
Hanall Biopharma's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $452.31 Million | $80.02 Billion | -$7.08 Billion | 0.01x | N/A |
| 2016 | $452.31 Million | $82.88 Billion | $2.03 Billion | 0.01x | 0.22x |
| 2017 | $839.26 Million | $84.23 Billion | $5.81 Billion | 0.01x | 0.14x |
| 2018 | $1.25 Billion | $91.84 Billion | $3.30 Billion | 0.01x | 0.38x |
| 2019 | $1.25 Billion | $108.45 Billion | $19.17 Billion | 0.01x | 0.07x |
| 2020 | $1.29 Billion | $88.60 Billion | $19.76 Billion | 0.01x | 0.07x |
| 2021 | $724.03 Million | $101.59 Billion | $8.90 Billion | 0.01x | 0.08x |
| 2022 | $612.25 Million | $110.00 Billion | $251.47 Million | 0.01x | 2.43x |
| 2023 | $1.52 Billion | $134.91 Billion | $3.51 Billion | 0.01x | 0.43x |
| 2024 | $1.33 Billion | $138.94 Billion | -$1.80 Billion | 0.01x | N/A |
Competitor Companies of 009420 by Market Capitalization
Companies near Hanall Biopharma in the global market cap rankings as of November 1, 2026. Also see 009420 total assets for a full breakdown of the balance sheet.
Key companies related to Hanall Biopharma by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Hanall Biopharma (2015–2026)
Market capitalization of Hanall Biopharma from 2015 to today. Between 2015 and today, Hanall Biopharma's market cap moved from $452.31 Million to $ 1.29 Billion, with a yearly change of 10.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.29 Billion | -14.29% |
| 2025 | ₩1.50 Billion | +13.20% |
| 2024 | ₩1.33 Billion | -12.75% |
| 2023 | ₩1.52 Billion | +148.88% |
| 2022 | ₩612.25 Million | -15.44% |
| 2021 | ₩724.03 Million | -43.87% |
| 2020 | ₩1.29 Billion | +3.31% |
| 2019 | ₩1.25 Billion | +0.28% |
| 2018 | ₩1.25 Billion | +48.36% |
| 2017 | ₩839.26 Million | +85.55% |
| 2016 | ₩452.31 Million | 0.00% |
| 2015 | ₩452.31 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Hanall Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.29 Billion USD |
| MoneyControl | $1.29 Billion USD |
| MarketWatch | $1.29 Billion USD |
| marketcap.company | $1.29 Billion USD |
| Reuters | $1.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more